| Abstrakt: |
A recent study conducted at Beaumont Hospital in Dublin, Ireland, examined the management and outcomes of delayed cerebral ischemia (DCI) associated with vasospasm post nontraumatic subarachnoid hemorrhage (SAH). The study found that DCI is the leading cause of adverse outcomes in patients who survive the initial phase of SAH. While induced hypertension is recommended as a first-line treatment for DCI, there is no high-level evidence confirming its outcome benefit. The study analyzed data from 532 patients admitted with SAH, of which 68 developed vasospasm. The subgroup of patients who received hypertensive therapy with norepinephrine alone had better outcomes compared to those who received both norepinephrine and vasopressin. The study concluded that there was no correlation between the percentage of days that mean arterial pressure (MAP) targets were met and improved patient outcomes. Patients who required dual therapy to achieve MAP targets had significantly worse neurological outcomes. [Extracted from the article] |
